CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 73 enrolled
Drug / intervention
Electric Acoustic Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00747435
NCT00747435N/ACompleted
CompareCT.gov

The MED-EL EAS (Electric-Acoustic System) Using the PULSARCI100 FLEXeas / SONATATI100 FLEXeas and the DUET Speech Processor

Med-El Corporation·interventional·Posted Sep 5, 2008·Updated May 17, 2017

In Brief

A clinical study evaluating Electric Acoustic System for Hearing Loss. Completed, enrolled 73 participants across 14 sites.

Detailed Summary

The purpose of this investigation is to demonstrate the safety and effectiveness of the MED-EL Electric-Acoustic System (EAS), a medical device that combines the use of a cochlear implant with an external electric-acoustic processor designed to provide benefit in speech perception and sound quality to individuals with a sensorineural hearing loss with minimal changes in residual hearing. The acoustic component of the processor will aid residual acoustic hearing in low frequency ranges, while the cochlear implant and electric component of the processor will be used to electrically stimulate the auditory nerve across a wide range of frequencies necessary for speech perception.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHearing Loss
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 5, 2008
Enrollment StartFeb 1, 2007
Primary CompletionFeb 1, 2016
TodayJul 2, 2026
Enrollment to primary: 9 yearsPosted 17.8 years ago

Interventions

Electric Acoustic Systemdevice

Combination of a cochlear implant and a hearing aid